BRPI0407840A - polipeptìdeo purificado, anticorpo policlonal ou monoclonal purificado, vetor de expressão, seqüência de polinucleotìdeo purificada, uso de uma seqüência de polinucleotìdeo, vetor viral recombinante, vìrus do sarampo recombinante, composição farmacêutica, uso da mesma, célula hospedeira, método para produzir um vìrus recombinante para a produção de um vìrus recombinante, linhagem de células, ensaio de neutralização de vìrus do nilo ocidental, e, método para tratar e/ou prevenir uma infecção ou doença associada com wnv ou vìrus do dengue em um animal - Google Patents

polipeptìdeo purificado, anticorpo policlonal ou monoclonal purificado, vetor de expressão, seqüência de polinucleotìdeo purificada, uso de uma seqüência de polinucleotìdeo, vetor viral recombinante, vìrus do sarampo recombinante, composição farmacêutica, uso da mesma, célula hospedeira, método para produzir um vìrus recombinante para a produção de um vìrus recombinante, linhagem de células, ensaio de neutralização de vìrus do nilo ocidental, e, método para tratar e/ou prevenir uma infecção ou doença associada com wnv ou vìrus do dengue em um animal

Info

Publication number
BRPI0407840A
BRPI0407840A BRPI0407840-3A BRPI0407840A BRPI0407840A BR PI0407840 A BRPI0407840 A BR PI0407840A BR PI0407840 A BRPI0407840 A BR PI0407840A BR PI0407840 A BRPI0407840 A BR PI0407840A
Authority
BR
Brazil
Prior art keywords
virus
recombinant
purified
polynucleotide sequence
wnv
Prior art date
Application number
BRPI0407840-3A
Other languages
English (en)
Inventor
Frederic Tangy
Philippe Despres
Chantal Combredet
Marie Pascale Frenkiel
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002420092A external-priority patent/CA2420092A1/en
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of BRPI0407840A publication Critical patent/BRPI0407840A/pt
Publication of BRPI0407840B1 publication Critical patent/BRPI0407840B1/pt
Publication of BRPI0407840B8 publication Critical patent/BRPI0407840B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"POLIPEPTìDEO PURIFICADO, ANTICORPO POLICLONAL OU MONOCLONAL PURIFICADO, VETOR DE EXPRESSãO, SEQüêNCIA DE POLINUCLEOTìDEO PURIFICADA, USO DE UMA SEQüêNCIA DE POLINUCLEOTìDEO, VETOR VIRAL RECOMBINANTE, VìRUS DO SARAMPO RECOMBINANTE, COMPOSIçãO FARMACêUTICA, USO DA MESMA, CéLULA HOSPEDEIRA, MéTODO PARA PRODUZIR UM VìRUS RECOMBINANTE PARA A PRODUçãO DE UM VìRUS RECOMBINANTE, LINHAGEM DE CéLULAS ENSAIO DE NEUTRALIZAçãO DE VìRUS DO NILO OCIDENTAL, E, MéTODO PARA TRATAR E/OU PREVENIR UMA INFECçãO OU DOENçA ASSOCIADA COM WNV OU VìRUS DO DENGUE EM UM ANIMAL". A presente invenção refere-se ao desenvolvimento de vetores virais expressando diferentes imunógenos do virus da encefalite do Nilo Ocidental (WNV, West Nile Encephalitis Virus) ou do vírus do Dengue que são capazes de induzir respostas celulares e humorais protetoras contra infecções com vírus WNV ou do Dengue. Mais especificamente, a presente invenção refere-se a três (3) antígenos do WNV (a glicoproteína (E) do envelope secretada, as glicoproteínas de heterodímero (pre-M-E) e a proteína NSI) e do vírus do Dengue (a glicoproteína (e) do envelope secretada, as glicoproteínas de heterodímero (pre-m-e) e a proteína ns1) e seu uso em aplicações vacinais, terapêuticas e diagnósticas.
BRPI0407840A 2003-02-26 2004-02-26 vírus do sarampo recombinante, composição farmacêutica, uso de uma composição farmacêutica, célula bacteriana, método para produzir um vírus recombinante e uso BRPI0407840B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA2.420.092 2003-02-26
CA002420092A CA2420092A1 (en) 2003-02-26 2003-02-26 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA002432738A CA2432738A1 (en) 2003-02-26 2003-06-20 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2.432.738 2003-06-20
PCT/IB2004/001027 WO2004076619A2 (en) 2003-02-26 2004-02-26 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications

Publications (3)

Publication Number Publication Date
BRPI0407840A true BRPI0407840A (pt) 2006-02-14
BRPI0407840B1 BRPI0407840B1 (pt) 2020-05-26
BRPI0407840B8 BRPI0407840B8 (pt) 2021-05-25

Family

ID=32909240

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407840A BRPI0407840B8 (pt) 2003-02-26 2004-02-26 vírus do sarampo recombinante, composição farmacêutica, uso de uma composição farmacêutica, célula bacteriana, método para produzir um vírus recombinante e uso

Country Status (9)

Country Link
US (2) US7556812B2 (pt)
EP (1) EP1599495B9 (pt)
BR (1) BRPI0407840B8 (pt)
CA (1) CA2432738A1 (pt)
DK (1) DK1599495T3 (pt)
ES (1) ES2394307T3 (pt)
HK (1) HK1086278A1 (pt)
IL (1) IL170418A (pt)
WO (1) WO2004076619A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233038D1 (de) 2002-06-20 2009-09-03 Pasteur Institut Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
EP1626708B1 (en) * 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
EP1740727A1 (en) 2004-04-30 2007-01-10 Baxter International Inc. System and method for detecting west nile virus
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
FR2871888A1 (fr) * 2004-06-22 2005-12-23 Pasteur Institut Methode de diagnostic ou de depistage d'une infection clinique ou asymptomatique par un flavivirus du groupe encephalitique
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CA2508266A1 (fr) * 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CN106377767A (zh) * 2008-05-26 2017-02-08 卡迪拉保健有限公司 麻疹‑人乳头瘤组合疫苗
CA2735164C (en) * 2008-08-29 2021-08-31 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
US20120141520A1 (en) * 2009-05-31 2012-06-07 Beth-Ann Coller Recombinant subunit west nile virus vaccine for protection of human subjects
EP2571990A4 (en) 2010-05-21 2013-11-20 Univ Pittsburgh UNIVERSAL DENGUE VIRUS SEQUENCES AND METHOD FOR THEIR USE
ES2842595T3 (es) 2011-03-14 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Vacuna contra la rinitis equina
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
WO2016110869A2 (en) * 2015-01-05 2016-07-14 Joshi Vishwas Dattatraya Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
US11459619B2 (en) 2016-02-08 2022-10-04 The Johns Hopkins University Handheld nucleic acid-based assay for rapid identification
EP3474892A1 (en) 2016-06-24 2019-05-01 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja) 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AU4427897A (en) * 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
HU228705B1 (en) 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
JP2003506039A (ja) 1999-08-02 2003-02-18 ワイス ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー
SI1317559T1 (sl) 2000-04-28 2009-04-30 St Jude Childrens Res Hospital Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna
CA2440593A1 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
DE60233038D1 (de) 2002-06-20 2009-09-03 Pasteur Institut Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
EP1694829B1 (fr) * 2003-12-02 2010-08-04 Institut Pasteur Nouvelle souche de coronavirus associe au sras et ses applications.
CA2508266A1 (fr) * 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
EP2058003A1 (en) * 2007-10-10 2009-05-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Medicaments and methods for treating mesothelioma
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
CN106377767A (zh) 2008-05-26 2017-02-08 卡迪拉保健有限公司 麻疹‑人乳头瘤组合疫苗
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2427201B1 (en) 2009-05-05 2015-01-28 Cadila Healthcare Limited Combined measles-malaria vaccine

Also Published As

Publication number Publication date
US20130089558A1 (en) 2013-04-11
BRPI0407840B8 (pt) 2021-05-25
HK1086278A1 (en) 2006-09-15
EP1599495B9 (en) 2013-11-13
BRPI0407840B1 (pt) 2020-05-26
CA2432738A1 (en) 2004-08-26
WO2004076619A2 (en) 2004-09-10
ES2394307T3 (es) 2013-01-30
US8859240B2 (en) 2014-10-14
EP1599495B1 (en) 2012-08-29
EP1599495A2 (en) 2005-11-30
US20060073164A1 (en) 2006-04-06
US7556812B2 (en) 2009-07-07
DK1599495T3 (da) 2012-12-03
IL170418A (en) 2014-11-30
WO2004076619A3 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
BRPI0407840A (pt) polipeptìdeo purificado, anticorpo policlonal ou monoclonal purificado, vetor de expressão, seqüência de polinucleotìdeo purificada, uso de uma seqüência de polinucleotìdeo, vetor viral recombinante, vìrus do sarampo recombinante, composição farmacêutica, uso da mesma, célula hospedeira, método para produzir um vìrus recombinante para a produção de um vìrus recombinante, linhagem de células, ensaio de neutralização de vìrus do nilo ocidental, e, método para tratar e/ou prevenir uma infecção ou doença associada com wnv ou vìrus do dengue em um animal
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
DE68919846D1 (de) Poxvirus-vektoren.
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
BRPI0807929A2 (pt) Anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, polipeptídeo isolado, composição, ácido nucleico isolado, vetor de expressão, célula hospedeira, vacina do vírus da hepatite c (hcv), kit, métodos para tratar e detectar uma infecção por vírus da hepatite c (hcv) e para identificar um anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo, e, proteína e2 recombinante do vírus da hepatite c (hcv)
BRPI1015917A2 (pt) antígenos de rsv recombinantes.
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
BR9815551A (pt) Vacina de envoltório dimérica recombinante contra infecção flaviviral
BRPI0510016B8 (pt) vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina
NO20081043L (no) Vaksine for fisk
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR0112020A (pt) Partìculas tipo vìrus de bvdv
Taylor et al. Interferons
Lorenzo et al. Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome
Naz et al. Expression of alpha and gamma interferon receptors in the sperm cell
EP1572721A4 (en) PREVENTING AND TREATING VCH INFECTION USING ANTIBODIES AGAINST CONFORMATIONAL AND LINEAR EPITOPES
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF